close

Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company's products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and GlucoBreak, a fat-free glucose spray. Generex Biotechnology Corporation's under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; and morphine and fentanyl products for breakthrough and postoperative pain. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S. The company was founded in 1983 and is based in Toronto, Canada.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	0.31
Volume	0
Volume Avg	(mio) 2.22
52 Week High	0.73
52 Week Low	0.26
PE	N/A
PE (group average)	39
EPS Year	0.00
EPS change Q/Q	-50%
EPS change Q/Q Yr ago	-50%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-75%
REV change Q/Q	-100%
REV change Q/Q Yr ago	-66.67%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%